Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company focused on rare and orphan diseases, announced it has obtained a license and distribution agreement with Hong Kong WinHealth Pharma Group Ltd. for its lead product candidate, QRX003 for Netherton Syndrome as well as for a second pipeline product, QRX004 for Epidermolysis Bullosa.
The agreement will enable Quoin to provide healthcare professionals and patients in greater China, including Hong Kong, Macau and Taiwan, with access to its products upon receiving regulatory approval. With this latest agreement, license and distribution partnerships have now been established for QRX003 in nearly 60 countries globally.
QRX003 has the capability to be the first approved treatment for Netherton Syndrome, a rare genetic disease affecting the skin and immune system which has no available treatments or cure. Quoin received FDA clearance of its Investigational New Drug (IND) in April 2022 and expects to initiate clinical testing this quarter.
Read more here